A Study of Onapristone ER Alone Or In Combination With Anastrozole in Gynecologic Cancers That Respond to Progesterone
The purpose of this study is to test any good and bad effect of the study drug, onapristone extended-release (ER) alone and in combination with anastrozole.
Granulosa Cell Ovarian Cancer|Low Grade Serous Ovarian/ Primary Peritoneal Cancer|Endometrioid Endometrial Cancer
DRUG: Onapristone ER|DRUG: Onapristone ER + Anastrozole
response rate, as determined by RECIST 1.1 response, within 36 weeks
The purpose of this study is to test any good and bad effect of the study drug, onapristone extended-release (ER) alone and in combination with anastrozole.